In short
Clinical trials investigating Somatropin are studying growth-related conditions in children and some related hormone and metabolism questions in adults. These studies look at how well treatment works, how safe it is, and how it compares with other growth hormone treatments in different patient groups.
Key points
- Clinical trials investigating Somatropin are mainly focused on children with growth problems, including growth hormone deficiency, being born small for gestational age, Turner syndrome, Noonan syndrome, and idiopathic short stature. The studies are mostly Phase 2 and Phase 3 trials, so they are testing both early effects and larger comparisons between treatments. Many trials compare weekly treatment options with daily Norditropin®, while one study looks at Somatropin with letrozole in boys with low predicted adult height. The main result being measured is height velocity, or how fast children grow over time. Some trials also measure final height, adult height gain, or changes in metabolism. One study includes adults with acromegaly and healthy people to explore how growth hormone affects liver fat and energy use.
Trial overview
The trial data show several studies that investigate Somatropin-related growth treatment in children and, in one study, hormone and metabolism questions in adults. Most of the studies are interventional trials, which means researchers give a treatment and then measure the results.
Who is being studied
Several trials focus on children with growth hormone deficiency, which means the body does not make enough growth hormone for normal growth. Other studies include children who were small for gestational age (SGA), children with Turner syndrome, Noonan syndrome, idiopathic short stature, or SHOX-D. One trial is in boys with short predicted height, meaning the study expects their adult height may be lower than average.
One Phase 2 study includes people with acromegaly and healthy volunteers, and it looks at metabolism in humans. This makes the trial set broader than growth studies alone, but the main focus across the data is still growth-related research.
Trial designs and phases
The listed studies are mainly in Phase 3, with two studies in Phase 2. Phase 2 studies usually look at early effects in a smaller group, while Phase 3 studies test treatment effects in larger groups and often compare different options. Enrollment ranges from 30 people to 412 people, showing that some studies are small and focused while others are larger comparison trials.
Several studies compare weekly treatment with daily treatment, especially weekly somapacitan-based regimens versus daily Norditropin®. One Phase 3 study compares daily Somatropin with weekly lonapegsomatropin in children and adolescents.
What the trials measure
The most common primary outcome is height velocity, which means how fast a child grows over time, usually measured in centimeters per year. One study measures height velocity from baseline to week 52, while another measures it from baseline to week 26. The Phase 3 GHD Reversal Trial measures Final Height in Standard Deviation Score (FH SDS), which compares final height with the average height expected for age and sex.
The OMNIMARA Trial measures adult height gain, defined as final height minus predicted adult height. The metabolism study measures GH-induced changes in energy-rich phosphate metabolism, including ATP turnover, which is a way to look at how the body uses energy. These outcomes show that the trials are not only checking whether treatment helps children grow, but also whether it changes longer-term height and body metabolism.
Key treatment comparisons
Several trials compare Somatropin-related weekly treatment with daily Norditropin®. In the growth hormone deficiency study, children receive somapacitan once a week or Norditropin® once a day. In the SGA study, children born small and who stayed small are also treated with weekly somapacitan or daily Norditropin®.
The study in children with short stature linked to SGA, Turner syndrome, Noonan syndrome, or idiopathic short stature aims to confirm that weekly somapacitan is non-inferior, meaning it is not worse than daily Norditropin® by more than a set amount. The Phase 3 trial in children with short predicted height tests whether combining GH treatment with letrozole during puberty gives more adult height gain than GH alone. Another Phase 3 study compares weekly lonapegsomatropin with daily Somatropin in children and adolescents with growth failure due to growth hormone sufficient disorders.
What these studies may mean for patients
For patients and families, these trials mainly ask whether different growth treatments can help children grow better, with fewer injections or different treatment schedules. The studies also try to understand whether treatment can improve final adult height, not only short-term growth. Because the trials include different growth conditions, they help researchers learn which children may benefit most from each treatment approach.